Divergent effects of low versus high dose anti-TGF-β antibody in puromycin aminonucleoside nephropathy in rats

Kidney International

Volumn 65, Issue 1, 2004, Pages 106-115

  Ma, Li Jun ^b   Jha, Sharda ^b   Ling, Hong ^b   Pozzi, Ambra ^b   Ledbetter, Steve ^b   Fogo, Agnes B ^a  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b NONE

Author keywords

Glomerulosclerosis; Kidney; Macrophage; PAI 1; TGF

Indexed keywords

COLLAGEN; COLLAGEN TYPE 3; CREATININE; GELATIN; GELATINASE A; GELATINASE B; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; HYDROXYPROLINE; MESSENGER RNA; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROLINE; PROTEIN; PUROMYCIN AMINONUCLEOSIDE; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA ANTIBODY; TRANSFORMING GROWTH FACTOR BETA1; TRANSFORMING GROWTH FACTOR BETA2;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CREATININE CLEARANCE; DOSE RESPONSE; DRUG EFFECT; ENZYME ACTIVITY; GENE EXPRESSION; GLOMERULOSCLEROSIS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; KIDNEY CORTEX; KIDNEY DISEASE; KIDNEY FUNCTION; MACROPHAGE; MALE; NONHUMAN; NORTHERN BLOTTING; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; SYSTOLIC BLOOD PRESSURE; ZYMOGRAPHY;

EID: 0346101487     PISSN: 00852538     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1523-1755.2004.00381.x     Document Type: Article

References (46)

1. BORDER WA, NOBLE NA: Transforming growth factor beta in tissue fibrosis. N Engl J Med 331:1286-1292, 1994
2. MUNGER JS, HUANG X, KAWAKATSU H, et al: The integrin alpha v beta 6 binds and activates latent TGF beta 1: A mechanism for regulating pulmonary inflammation and fibrosis. Cell 96:319-328, 1999
3. MA LJ, MARCANTONI C, LINTON MF, et al: Peroxisome proliferator-activated receptor-gamma agonist troglitazone protects against nondiabetic glomerulosclerosis in rats. Kidney Int 59:1899-1910, 2001
4. NAKAMURA T, EBIHARA E, FUKUI M, et al: Messenger RNA expression for growth factors in glomeruli from focal glomerular sclerosis. Clin Immunol Immunopathol 66:33-42, 1993
5. JONES CL, BUCH S, POST M, et al. Renal extracellular matrix accumulation in acute puromycin aminonucleoside nephrosis in rats. Am J Pathol 141:1381-1396, 1992
6. MIYAJIMA A, CHEN J, LAWRENCE C, et al: Antibody to transforming growth factor-beta ameliorates tubular apoptosis in unilateral ureteral obstruction. Kidney Int 58:2301-2313, 2000
7. MA L-J, NAKAMURA S, WHITSITT JS, et al: Regression of sclerosis in aging by an angiotensin inhibition-induced decrease in PAI-1 Kidney Int 58:2425-2436, 2000
8. YAMAMOTO T, NAKAMURA T, NOBLE NA, et al: Expression of transforming growth factor β is elevated in human and experimental diabetic nephropathy. Proc Natl Acad Sci USA 90:1814-1818, 1993
9. ISAKA Y, FUJIWARA Y, UEDA N, et al: Glomerulosclerosis induced by in vivo transfection of transforming growth factor-beta or platelet-derived growth factor gene into the rat kidney. J Clin Invest 92-2597-2601, 1993
10. SHARMA K, ZIYADEH FN: The emerging role of transforming growth factor-beta in kidney diseases. Am J Physiol 266:F829-F842, 1994
11. FOGO AB: Progression and potential regression of glomerulosclerosis (Nephrology Forum). Kidney Int 59:804-819, 2001
12. PETERS H, BORDER WA, NOBLE NA: Targeting TGF-β overexpression in renal disease: Maximizing the antifibrotic action of angiotensin II blockade. Kidney Int 54:1570-1580, 1998
13. BORDER WA, NOBLE NA, YAMAMOTO T, et al: Natural inhibitor of transforming growth factor-beta protects against scarring in experimental kidney disease. Nature 360:361-364, 1992
14. BORDER WA, OKUDA S, LANGUINO LR. et al: Suppression of experimental glomerulonephritis by antiserum against transforming growth factor beta 1. Nature 346:371-374, 1990
15. SHIBA KS, KANAMORI K, HARADA T, et al: A cause of discrepancy between values for urinary protein as assayed by the Coomassie Brilliant Blue G-250 method and the sulfosalicylic acid method. Clin Chem 31:1215-1218, 1985
16. GLUMOFF V, MAKELA JK, VUORIO E: Cloning of cDNA for rat pro alpha 1 (III) collagen mRNA. Different expression patterns of type I and type III collagen and fibronectin genes in experimental granulation tissue. Biochimica et Biophysica Acta 1217:41-48, 1994
17. DERYNCK R, JARRETT JA, CHEN EY, et al: Human transforming growth factor-beta complementary DNA sequence and expression in normal and transformed cells. Nature 316:701-705, 1985
18. WEBB NR, MADISEN L, ROSE TM: Structural and sequence analysis of TGF-beta2 cDNA clones predicts two different precursor proteins produced by alternative mRNA splicing. DNA 7:493-497, 1988
19. POZZI A, MOBERG PE, MILES LA, et al: Elevated matrix metalloprotease and angiostatin levels in integrin alpha 1 knockout mice cause reduced tumor vascularization. Proc Natl Acad Sci USA 97:2202-2207, 2000
20. ANDERSON S, DIAMOND J, KARNOVSKY M, et al: Mechanisms underlying transition from acute glomerular injury to late glomerular sclerosis in a rat model of nephrotic syndrome. J Clin Invest 82:1757-1768, 1988
21. OKUDA S, LANGUINO LR, RUOSLAHTI E, et al: Elevated expression of transforming growth factor-beta and proteoglycan production in experimental glomerulonephritis. Possible role in expansion of the mesangial extracellular matrix. J Clin Invest 86:453-462, 1990
22. ZIYADEH FN, HOFFMAN BB, HAN DC, et al: Long-term prevention of renal insufficiency, excess matrix gene expression, and glomerular mesangial matrix expansion by treatment with monoclonal anti-transforming growth factor-beta antibody in db/db diabetic mice. Proc Natl Acad Sci USA 97:8015-8020, 2000
23. WELLER M, CONSTAM DB, MALIPIERO U, et al: Transforming growth factor-beta 2 induces apoptosis of murine T cell clones without down-regulating bcl-2 mRNA expression. Eur J Immunol 24:1293-1300, 1994
24. NEURATH MF, Fuss I, KELSALL BL, et al: Experimental granulomatous colitis in mice is abrogated by induction of TGF-beta-mediated oral tolerance. J Exp Med 183:2605-2616, 1996
25. D'ORAZIO TJ, NIEDERKORN JY: A novel role for TGF-beta and IL-10 in the induction of immune privilege. J Immunol 160:2089-2098, 1998
26. MIGDALSKA A, MOLINEUX G, DEMUYNCK H, et al: Growth inhibitory effects of transforming growth factor-beta 1 in vivo. Growth Factors 4:239-245, 1991
27. SHULL MM, ORMSBY I, KIER AB, et al: Targeted disruption of the mouse transforming growth factor-beta 1 gene results in multifocal inflammatory disease. Nature 359:693-699, 1992
28. SANFORD LP, ORMSBY I, GITTENBERGER-DE GROOT AC, et al: TGF-beta2 knockout mice have multiple developmental defects that are non-overlapping with other TGFbeta knockout phenotypes. Development 124:2659-2670, 1997
29. SHANKLAND SJ, PIPPIN J, PICHLER RH, et al: Differential expression of transforming growth factor-beta isoforms and receptors in experimental membranous nephropathy. Kidney Int 50:116-124, 1996
30. BITZER M, STERZEL RB, BOTTINGER EP: Transforming growth factor-beta in renal disease. Kidney Blood Press Res 21:1-12, 1998
31. LEDBETTER S, KURTZBERG L, DOYLE S, et al: Renal fibrosis in mice treated with human recombinant transforming growth factor-beta2. Kidney Int 58:2367-2376, 2000
32. YANG X, LETTERIO JJ, LECHLEIDER RJ, et al: Targeted disruption of SMAD3 results in impaired mucosal immunity and diminished T cell responsiveness to TGF-beta. EMBO J 18:1280-1291, 1999
33. ASHCROFT GS, YANG X, GLICK AB, et al: Mice lacking Smad3 show accelerated wound healing and an impaired local inflammatory response. Nat Cell Biol 1:260-266, 1999
34. ASHCROFT GS, ROBERTS AB. Loss of Smad3 modulates wound healing. Cytokine Growth Factor Rev 11:125-131, 2000
35. YU XQ, WU LL, HUANG XR, et al. Osteopontin expression in progressive renal injury in remnant kidney: Role of angiotensin II. Kidney Int 58:1469-1480, 2000
36. DIAMOND JR: Macrophages and progressive renal disease in experimental hydronephrosis. Am J Kidney Dis 26:133-140, 1995
37. EDDY A: Role of cellular infiltrates in response to proteinuria. Am J Kidney Dis 37:S25-S29, 2001
38. FOGO AB: The role of angiotensin II and plasminogen activator inhibitor-1 in progressive glomerulosclerosis. Am J Kidney Dis 35:179-188, 2000
39. MA L-J, FOGO AB: Role of angiotensin II in glomerular injury. Semin Nephrol 21:544-553, 2001
40. OIKAWA T, FREEMAN M, LO W, et al: Modulation of plasminogen activator inhibitor-1 in vivo: A new mechanism for the anti-fibrotic effect of renin-angiotensin inhibition. Kidney Int 51:164-172, 1997
41. BROWN NJ, NAKAMURA S, MA L-J, et al: Aldosterone modulates plasminogen activator inhibitor-1 and glomerulosclerosis in vivo. Kidney Int 58:1219-1227, 2000
42. ODA T, JUNG YO. KIM HS, et al: PAI-1 deficiency attenuates the fibrogenic response to ureteral obstruction. Kidney Int 60:587-596, 2001
43. LENZ O, ELLIOT SJ, STETLER-STEVENSON WG. Matrix metalloproteinases in renal development and disease. J Am Soc Nephrol 11:574-581, 2000
44. LELONGT B, LEGALLICIER B, PIEDAGNEL R, RONCO PM. Do matrix metalloproteinases MMP-2 and MMP-9 (gelatinases) play a role in renal development, physiology and glomerular diseases? Curr Opin Nephrol Hypertens 10:7-12, 2001
45. JOHNSON TS, HAYLOR JL, THOMAS GL, et al. Matrix metalloproteinases and their inhibitions in experimental renal scarring. Exp Nephrol 10:182-195, 2002
46. TANAKA R, KON V, YOSHIOKA T, et al. Angiotensin converting enzyme inhibitor modulates glomerular function and structure by distinct mechanisms. Kidney Int 45:537-543, 1994